Anesthesia

"internal jugular, subclavian, and femoral approaches — indications, advantages and complications [3]. Outline the immediate and delayed complications of CVC insertion and how to confirm correct placement [3]. ⚙ Core Concept Central venous catheterisation is a core procedural skill in anaesthesia and critical care — used for drug delivery, haemodynamic monitoring, renal replacement therapy, and cardiac pacing. Ultrasound guidance has transformed the safety of CVC insertion, reducing arterial puncture rates from 5–10% (landmark technique) to <1% (USG). (Sznajder JI — CVC complications; McGee DC — evidence for CVC complications; NICE guidance TA49; Miller's Anaesthesia 9th Ed) A. Right Internal Jugular Anatomy and USG Technique 4 marks Anatomy: right IJ runs within the carotid sheath; at the level of the cricoid cartilage (C6): IJ lies anterior and lateral to the carotid artery; at the base of the neck: IJ lies anterolateral to the common carotid → joins subclavian vein to form the brachiocephalic vein; the right IJ is preferred for CVC because: (1) straight path to the SVC (left IJ has an acute angle at the left brachiocephalic junction → more difficult); (2) avoids the thoracic duct (on the left); (3) landmark: apex of the triangle between sternal and clavicular heads of sternocleidomastoid (SCM) Ultrasound-guided technique (NICE TA49 — mandatory for IJ CVC in elective settings): Position: patient supine, head 15° Trendelenburg (↑ IJ diameter + reduces air embolism risk); head turned slightly to the left (exposes right neck); sterile field USG probe: high-frequency linear probe (7–12 MHz); apply sterile sheath + sterile gel; identify IJ in short axis (transverse view): IJ = compressible anechoic (black) circular structure; carotid = pulsatile non-compressible, anterior and medial to IJ; confirm: compression collapses IJ not carotid; Doppler shows venous flow in IJ Needle insertion: under continuous real-time USG guidance; needle visualised as hyperechoic dot entering the IJ in short-axis view; confirm intraluminal position (needle tip seen inside IJ lumen) before advancing guide wire Seldinger technique: aspirate blood (dark, non-pulsatile = venous); confirm with transduction or blood gas (PvO₂ vs PaO₂); thread J-wire through needle; remove needle; nick skin at wire entry point; thread dilator over wire (hold wire at all times — prevent embolisation); remove dilator; thread CVC over wire; remove wire; aspirate and flush all lumens Confirm placement: CXR (tip at the cavoatrial junction — junction of SVC and right atrium — or SVC 2 cm above); exclude pneumothorax; tip position: ideal = SVC/RA junction (not in RA — risk of cardiac perforation or arrhythmia); not in a small vein or contralateral) B. IJ vs Subclavian vs Femoral — Comparison 3 marks Feature Right Internal Jugular Subclavian Femoral Infection risk (CLABSI) Intermediate LOWEST (preferred for long-term lines) HIGHEST (proximity to perineum — avoid if possible; use only in emergency) DVT risk Intermediate Lowest HIGHEST (femoral DVT + PE risk) Pneumothorax risk Low (with USG) HIGHER — needle passes above clavicle under pleura (not compressible with USG — landmark technique has 1–2% pneumothorax) None Arterial puncture risk Low with USG (<1%) Subclavian artery injury — difficult to compress (behind clavicle) Femoral artery puncture — easily compressible Preferred use Standard first choice (USG); emergency; haemodynamic monitoring; Swan-Ganz Long-term (TPN, chemotherapy); coagulopathy (compressible); when IJ not possible Emergency — fastest access in cardiac arrest; coagulopathy (most compressible) C. Complications and Confirmation of Placement 3 marks Immediate complications: arterial puncture (5–10% landmark; <1% USG) → remove needle + apply pressure; if dilator advanced into carotid → DO NOT remove — surgical consultation (removing a dilator from carotid → massive haemorrhage); air embolism (head-down position + cap all ports immediately); cardiac arrhythmias during wire/catheter insertion (usually transient from wire in RV — withdraw slightly); pneumothorax (subclavian approach); haemothorax; thoracic duct injury (left-sided approach) Delayed complications: central line-associated bloodstream infection (CLABSI) — Staphylococcus epidermidis most common; catheter-associated thrombosis; catheter malposition (kinking in subclavian bend, migration to right atrium — arrhythmias, cardiac perforation → tamponade); catheter fracture/embolism; superior vena cava perforation (rare — can cause haemorrhage or chylothorax); fibrin sheath formation → difficult aspiration Confirming correct placement: CXR (tip at SVC-RA junction — level of carina on CXR); transduction (waveform — CVP trace should be biphasic venous waveform, NOT pulsatile arterial); blood gas comparison (central venous PO₂ < arterial PO₂ confirms venous position); contrast CT in doubt; ECG-guided catheter tip positioning (emerging — QRS amplitude changes as tip enters the heart) ★ Examiner's Pearl Right IJ preferred: straight path to SVC, avoids thoracic duct, compressible. NICE TA49: USG mandatory for IJ CVC in elective settings. IJ USG: compressible + non- pulsatile = vein; pulsatile non-compressible = carotid. CLABSI risk order: subclavian (lowest) < IJ < femoral (highest — avoid if possible). DVT risk: femoral highest. Pneumothorax: subclavian highest (non-compressible landmark technique). CXR tip position: SVC/RA junction (level of carina). References: NICE Technology Appraisal 49 (TA49). Ultrasound locating devices for placing central venous catheters (2002). McGee DC, Gould MK. Preventing complications of central venous catheterization (NEJM 2003;348:1123-1133). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"management [4]. Explain myocardial protection strategies including cardioplegia [3]. Outline the haemodynamic management of protamine administration and its adverse effects [3]. ⚙ Core Concept Cardiopulmonary bypass is the technological foundation of open-heart surgery — temporarily assuming the roles of the heart (pump function) and lungs (gas exchange) while the surgeon operates on a still, bloodless heart. Its physiological consequences are profound and multisystemic. Myocardial protection — preventing ischaemic injury to the arrested heart — is the key technical challenge of cardiac surgery. (Gravlee GP — CPB textbook; Buckberg GD — cardioplegia; Cook DJ; Miller's Anaesthesia 9th Ed) A. Principles of CPB 4 marks CPB components: (1) venous reservoir — collects blood draining by gravity from the right heart via venous cannulae (placed in SVC and IVC, or a single two- stage RA cannula); (2) oxygenator — membrane oxygenator (hollow fibre polypropylene membrane) replaces lung function: O₂ delivered + CO₂ removed via gas flow across the membrane; heat exchanger integrated for temperature control; (3) arterial pump — roller pump (non-occlusive) or centrifugal pump; delivers blood at a set flow rate back into the aorta via the aortic cannula; (4) arterial filter — removes microemboli (air, particles) from the oxygenated blood before it enters the aortic cannula; (5) cardiotomy suction — aspirates blood from the operative field → returns to reservoir (defoamed and filtered); (6) heparinisation — systemic heparin 300–400 U/kg to achieve ACT (activated clotting time) >480 seconds before CPB (prevents clotting in the circuit) Physiological consequences of CPB: non-pulsatile flow (↓ renal perfusion, ↑ RAAS, ↓ microvascular autoregulation — see AKI Q53); haemodilution (prime volume 1–1.5 L crystalloid → ↓ Hb, ↓ colloid oncotic pressure); hypothermia (moderate 28–32°C) — ↓ metabolic rate (protective but → coagulopathy, arrhythmias); SIRS (blood-foreign surface contact → complement activation → cytokine release → capillary leak → post-bypass oedema and organ dysfunction); gaseous and particulate microemboli (→ neurocognitive dysfunction — ""pumphead"" syndrome: subtle cognitive impairment in 30–80% after CABG — reduced with membrane oxygenators vs bubble); coagulopathy (haemodilution + consumption + platelet dysfunction from pump circuit) Management during CPB: MAP 50–80 mmHg (autoregulation range in adults); flow 2.4 L/min/m²; haematocrit target 21–25% (minimum); temperature monitoring (nasopharyngeal + rectal); ACT every 30 min (maintain >480s); glucose control (hyperglycaemia → worse neurological outcomes — target BGL 6– 10 mmol/L) B. Myocardial Protection — Cardioplegia 3 marks Goals of myocardial protection: achieve rapid cardiac arrest (still field for surgery); maintain arrest during the ischaemic period; maximise recovery of cardiac function on reperfusion; prevent ischaemia-reperfusion injury Cardioplegia types: Cold crystalloid cardioplegia (St Thomas' solution): high K ⁺ (20–25 mEq/L → depolarises and arrests the heart in diastole); hypothermia (4°C — ↓ CMRO₂ equivalent ↓ myocardial metabolic demand); repeated doses every 20–30 min to maintain arrest and hypothermia Blood cardioplegia (Buckberg — warm or tepid blood cardioplegia + high K ⁺ ): uses the patient's own blood as the vehicle → delivers O₂ and nutrients even during arrest; superior metabolic protection compared to crystalloid; ""warm induction"" of arrest + cold maintenance + warm reperfusion (""hot shot"") Del Nido solution (currently popular for paediatric and adult cardiac surgery): single dose provides 60–90 min of arrest; higher Mg² ⁺ (membrane stabilisation); mannitol and lidocaine additives; reduces the number of re-dose interruptions to surgery Delivery routes: antegrade (into the aortic root via the aortic root cannula → flows into coronary ostia); retrograde (into coronary sinus → delivers to myocardium even when coronary arteries are severely diseased — useful in CABG); combined: antegrade + retrograde provides most complete distribution C. Protamine Administration and Adverse Effects 3 marks Protamine — heparin reversal: at the end of CPB, heparin must be neutralised to restore coagulation; protamine is a strongly positively-charged protein (from salmon sperm) that forms electrostatic complexes with heparin (strongly negatively charged) → inactive complex excreted by kidneys; dose: 1 mg protamine per 100 U of initial heparin dose (1:1 ratio); given over 10–15 minutes (slow administration reduces adverse reactions); ACT used to confirm heparin reversal (target ACT returns to baseline ± 10%); residual heparin monitored by heparin assay or anti-Xa Adverse effects of protamine: Type I (hypotension): most common — rapid injection → systemic vasodilation + ↓ CO → ↓ MAP; mechanism: direct vasoactive effect; management: slow the infusion rate; phenylephrine/noradrenaline; vasopressin Type II (anaphylactic/anaphylactoid): IgE-mediated or complement-mediated; ↑ risk in: fish allergy (cross-react with salmon protamine); NPH insulin users (protamine-insulin conjugate → sensitisation — 50× higher risk → use regular insulin or analogues perioperatively in cardiac surgery); prior vasectomy (anti-sperm antibodies may cross-react); treatment: adrenaline, antihistamines, steroids; may require going back on CPB Type III (pulmonary hypertension): protamine-heparin complexes activate complement → thromboxane release → massive pulmonary vasoconstriction → acute right heart failure; rare but potentially catastrophic; presentation: sudden ↑ PAP + ↓ CO + ↑ RV dilation on TOE; management: inhaled NO, inhaled prostaglandins, sildenafil; may require ECMO ★ Examiner's Pearl CPB ACT target: >480 seconds (heparinisation). CPB flow: 2.4 L/min/m² (non-pulsatile). SIRS on CPB: blood-foreign surface → complement activation → cytokine SIRS → post-bypass organ dysfunction. Cardioplegia arrest mechanism: high K ⁺ (depolarises + arrests in diastole). Protamine adverse effects: Type I = hypotension (slow infusion); Type II = anaphylaxis (↑ risk: fish allergy, NPH insulin, vasectomy); Type III = pulmonary hypertension (thromboxane complement-mediated → RV failure → inhaled NO). References: Gravlee GP et al. Cardiopulmonary Bypass: Principles and Practice, 3rd Ed. Buckberg GD. A proposed ""solution"" to the cardioplegic controversy (J Thorac Cardiovasc Surg 1979;77:803-815). Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 67."

"neuropathic pain [4]. Outline the pharmacological management of neuropathic pain with mechanisms of action [4]. ⚙ Core Concept Chronic pain is not simply prolonged acute pain — it is a distinct pathophysiological state in which the nervous system itself is altered: central sensitisation, peripheral sensitisation, structural reorganisation, and descending disinhibition create a self-sustaining pain state independent of the original injury. Neuropathic pain (WHO: pain caused by a lesion or disease of the somatosensory nervous system) affects 7–10% of the population and is notoriously refractory to conventional analgesics. (Treede RD — NeuPSIG neuropathic pain definition; Woolf CJ — central sensitisation; IASP Chronic Pain Classification; Finnerup NB — NeuPSIG pharmacological treatment guidelines 2015) A. Definitions — Chronic vs Acute Pain 2 marks Acute pain (IASP): pain of recent onset, usually with an identifiable cause; serves a biological protective function — warns of actual or impending tissue damage; typically resolves as healing occurs; associated with autonomic activation (tachycardia, hypertension, diaphoresis); responds to conventional analgesics (paracetamol, NSAIDs, opioids) Chronic pain (IASP, ICD-11 definition): pain persisting or recurring for more than 3 months; may occur with or without identifiable ongoing tissue damage; the biological protective purpose is lost — chronic pain itself becomes the disease; ICD-11 (2019) introduced ""Chronic Primary Pain"" (e.g., fibromyalgia, chronic widespread pain — pain is the primary disorder) and ""Chronic Secondary Pain"" (chronic pain as a symptom of an identified underlying condition — e.g., chronic cancer pain, chronic post-surgical pain, chronic neuropathic pain); in chronic pain: autonomic activation is often absent; conventional analgesics frequently inadequate Chronic post-surgical pain (CPSP): pain developing after surgical procedure, persisting beyond 3 months, when other causes excluded; incidence after major surgery: thoracotomy 30–50%, mastectomy 20–30%, inguinal hernia repair 10–15%; major risk factors: pre-operative pain, high acute post-operative pain, nerve injury during surgery, psychological vulnerability (catastrophising, anxiety) B. Central Sensitisation & Neuropathic Pain Mechanisms 4 marks Peripheral Sensitisation Tissue injury/inflammation → release of inflammatory mediators (bradykinin, prostaglandins, H ⁺ , NGF, substance P, glutamate) → activation of TRPV1 (transient receptor potential vanilloid 1 — the ""pain receptor"" for heat and capsaicin) and TRPA1 channels on C-fibre nociceptors → ↓ activation threshold (primary hyperalgesia — pain from stimuli at the site of injury that were previously not painful or less painful); also: previously ""silent"" C-nociceptors become active in inflamed tissue → expanded receptive field Central Sensitisation (Woolf CJ, 1983 — described in dorsal horn) Wind-up and NMDA receptor activation: repetitive C-fibre stimulation → repeated release of glutamate + substance P into the dorsal horn → glutamate binds AMPA receptors initially (short EPSPs) → sustained depolarisation displaces Mg² ⁺ blocking the NMDA channel → NMDA receptors now activated (normally blocked by Mg² ⁺ at resting potential) → ↑ Ca² ⁺ influx → activation of protein kinases (PKA, PKC) → phosphorylation of NMDA and AMPA receptors → ↑ receptor sensitivity and expression → ""wind-up"" — each subsequent stimulus produces greater and longer response; this is the cellular basis of central sensitisation Consequences of central sensitisation: (1) Allodynia — pain from normally non-painful stimuli (e.g., light touch via Aβ-fibre activation of sensitised dorsal horn neurons — the spinal cord now responds to innocuous input as if it were noxious); (2) Secondary hyperalgesia — pain hypersensitivity in tissue surrounding (but not at) the site of injury; (3) Expanded receptive fields — spinal neurones respond to stimuli from a wider area; (4) Temporal summation — increasing pain from repeated identical stimuli Descending pain modulation failure: normally, descending inhibitory pathways (locus coeruleus → noradrenaline; raphe nuclei → serotonin; PAG → endorphins) suppress dorsal horn transmission; in chronic pain states: descending inhibition is reduced + descending facilitation (from rostral ventromedial medulla) is enhanced → the spinal cord is no longer appropriately ""gated"" Structural reorganisation: chronic pain → sprouting of Aβ-fibres into superficial dorsal horn laminae (normally occupied only by C and Aδ nociceptors) → touch stimuli now physically access the pain-processing circuitry → structural basis of allodynia that is self-sustaining even after peripheral healing Neuropathic Pain — Specific Mechanisms Mechanism Pathophysiology Clinical Example Ectopic discharge Damaged peripheral nerve → abnormal Na ⁺ channel expression (Nav1.3, Nav1.8) at the site of injury (neuroma) and in the dorsal root ganglion → spontaneous high-frequency firing without peripheral stimulus Burning shooting pain in PHN, diabetic neuropathy; pain at rest; ""electric shock"" character Sympathetically maintained pain α-adrenoceptors expressed on regenerating nociceptors → sympathetic activity directly activates pain fibres; sympatho-afferent coupling at the DRG CRPS Type I/II — sympathetic blocks (stellate ganglion, lumbar sympathetic) provide relief Loss of inhibitory interneurons Nerve injury → death of GABA-ergic and glycinergic inhibitory interneurons in the dorsal horn → disinhibition → spinal cord ""hyperexcitable"" without normal gating Allodynia to light touch after nerve injury; gabapentin/pregabalin partially restores inhibitory tone C. Pharmacological Management of Neuropathic Pain (NeuPSIG Guidelines 2015) 4 marks Drug Class Examples & Doses Mechanism NBS / NNT Gabapentinoids (FIRST LINE) Pregabalin 75–300 mg BD; Gabapentin 300– 1200 mg TDS Bind α₂δ-1 subunit of voltage-gated Ca² ⁺ channels in the dorsal horn → ↓ Ca² ⁺ influx → ↓ release of excitatory neurotransmitters (glutamate, substance P) from central terminals of primary afferents; reduce wind-up and central sensitisation; also have anxiolytic properties (useful in pain- anxiety comorbidity) NNT ~6 for ≥50% pain relief; onset 1–2 weeks; side effects: sedation, dizziness, peripheral oedema, cognitive blunting; abuse potential (pregabalin Schedule 3 CD in UK since 2019) TCAs — tricyclic antidepressants (FIRST LINE) Amitriptyline 10–75 mg nocte; Nortriptyline (preferred in elderly — less anticholinergic) Inhibit reuptake of noradrenaline and serotonin in descending inhibitory pathways (NAd > 5-HT for analgesic effect) → ↑ descending inhibition of dorsal horn; also: Na ⁺ channel block (membrane stabilisation → ↓ ectopic discharge); NMDA antagonism; analgesic effect is independent of antidepressant effect (seen at lower doses, faster onset) NNT ~4; excellent evidence for diabetic neuropathy and PHN; side effects: anticholinergic (dry mouth, urinary retention, constipation), QTc prolongation (ECG before use in cardiac patients), sedation (useful if pain disrupts sleep); contraindicated in recent MI, arrhythmias, glaucoma SNRIs (FIRST LINE) Duloxetine 30–120 mg daily; Venlafaxine 75– 225 mg daily Serotonin and noradrenaline reuptake inhibitor → ↑ descending inhibition (noradrenergic pathway most important for analgesia); fewer side effects than TCAs; duloxetine has strongest evidence for diabetic peripheral neuropathy (approved by FDA/EMA for this indication) and fibromyalgia NNT ~6; side effects: nausea (dose with food), hypertension (venlafaxine — check BP), sexual dysfunction; safer than TCAs in cardiac disease; avoid abrupt withdrawal Topical agents (FIRST LINE for localised neuropathic pain) Lidocaine 5% patch (Versatis); Capsaicin 8% patch (Qutenza — high-concentration, single application clinic procedure) Lidocaine 5%: Na ⁺ channel block in the skin → ↓ ectopic peripheral discharge without systemic absorption; capsaicin 8%: TRPV1 agonist → massive Ca² ⁺ influx → temporary defunctioning of C-fibres (""defunctionalisation"") → reduced nociceptor density in skin for 3–6 months Lidocaine patch NNT ~4 for PHN; capsaicin 8% effective for PHN and HIV neuropathy; minimal systemic side effects — ideal for elderly/polypharmacy; capsaicin 8% requires topical anaesthetic pre-treatment and clinic application Opioids (SECOND LINE) Tramadol 50–100 mg QDS (weak opioid + SNRI); Tapentadol (MOR agonist + NAd reuptake inhibitor); Strong opioids (morphine, oxycodone) — third line Tramadol: μ-opioid receptor (weak — 1/6000th morphine) + serotonin and noradrenaline reuptake inhibition → dual mechanism; tapentadol: μ-opioid + stronger NAd reuptake inhibition (ratio NAd:MOR more favourable than tramadol → better neuropathic efficacy, fewer GI side effects); strong opioids: μ-receptor activation → dorsal horn inhibition, descending pathway activation; evidence for neuropathic pain but addiction risk limits long-term use Tramadol NNT ~5; risk of serotonin syndrome (avoid with SSRIs/MAOIs); tramadol lowers seizure threshold; strong opioids: ↑ risk of addiction, hyperalgesia (OIH), endocrine effects; use only if first/second-line failed; lowest effective dose; regular review ★ Examiner's Pearl Central sensitisation: wind-up → NMDA receptor activation (Mg² ⁺ block removed by sustained depolarisation) → ↑ Ca² ⁺ → PKC phosphorylation → ↑ receptor sensitivity → allodynia + secondary hyperalgesia + expanded receptive fields. NeuPSIG first-line for neuropathic pain: gabapentinoids (α₂δ Ca² ⁺ channel), TCAs (NAd reuptake + Na ⁺ block), SNRIs (duloxetine — DPN), topical lidocaine/capsaicin 8%. Second-line: tramadol (μ + SNRI). Amitriptyline: NNT ~4, best evidence; check ECG. Pregabalin: Schedule 3 CD in UK. NMDA antagonists (ketamine, memantine): adjuncts in refractory cases. References: Finnerup NB et al. Pharmacotherapy for neuropathic pain — NeuPSIG (Lancet Neurol 2015;14:162-173). Woolf CJ. Central sensitisation (Pain 2011;152:S2-S15). Treede RD et al. Neuropathic pain: redefinition (Neurology 2008;70:1630-1635). IASP Chronic Primary Pain ICD-11 Classification 2019. Wall PD, Melzack R. Textbook of Pain, 6th Ed."

"framework as applied to error prevention in anaesthesia [4]. Explain the WHO Surgical Safety Checklist and the role of critical incident reporting in improving patient safety [3]. ⚙ Core Concept Anaesthesia is intrinsically a high-risk, high-reliability industry — the anaesthetist administers potent drugs with narrow therapeutic indices to unconscious patients who cannot report symptoms. Drug errors are the most common preventable cause of anaesthetic harm — estimated to occur in 1 in 133 anaesthetics (Webster 2001). The human factors approach (from aviation safety science) and structured systems interventions (WHO Checklist, AIMS) have transformed patient safety. (Webster CS — drug error incidence; Reason J — Swiss Cheese Model; WHO Surgical Safety Checklist 2009; NPSA/NRLS; NAP reports; Flin R — human factors in anaesthesia) A. Types and Causes of Drug Errors in Anaesthesia 3 marks Incidence: Webster et al. (2001): drug administration errors in 1 in 133 anaesthetics (0.75%); Orser et al. (2001): 1 in 10 hospital drug orders contain an error; Merry et al.: systematic review suggests drug errors may be even more frequent — many go undetected; approximately 1 in 300 anaesthetic drug errors results in serious patient harm Error Type Definition Anaesthetic Examples Frequency Wrong drug (substitution error) A drug different from the one intended is administered Suxamethonium given instead of vecuronium (both clear solutions, adjacent on the trolley); adrenaline 1:1,000 instead of 1:10,000 (10× overdose); morphine instead of midazolam (similar syringe labelling) Most common drug error class — ~40% of all anaesthetic drug errors Wrong dose Correct drug but incorrect amount Paediatric weight-based dosing errors (e.g., propofol 200 mg instead of 20 mg due to decimal error); neostigmine 5 mg instead of 2.5 mg; 10-fold concentration errors with infusions (e.g., noradrenaline concentration mix-up) ~25% of errors; most dangerous in paediatrics and high-alert drugs Wrong route Drug given by an unintended route Epidural drug given IV (e.g., concentrated KCl intended for epidural, given IV); IV drug given epidurally; oral drug given IV; IV potassium chloride bolus (classic fatal error) Rare but frequently fatal — wrong-route errors have disproportionate harm Wrong patient Drug intended for one patient given to another Allergy-listed drug administered after a handover; blood transfusion ABO mismatch (wrong patient — see SHOT) Rare in anaesthesia; more common in ward drug administration Omission errors Failure to give a required drug Failure to give antibiotic prophylaxis; failure to give thromboprophylaxis; failure to give reversal agent Common and often undetected — particularly antibiotic timing errors Timing errors Drug given at the wrong time Antibiotic given 2h after incision (prophylaxis window missed); anticoagulant given too early after neuraxial block Significant — timing of antibiotics critically affects SSI rates Root Causes of Drug Errors (Reason's Error Taxonomy) Slips and lapses (skill-based errors): errors of execution in a well-known task — attention failure; e.g., picking up the wrong ampoule during induction under cognitive pressure; most drug substitution errors are slips Mistakes (rule/knowledge-based errors): wrong intention even if execution is correct; e.g., choosing an incorrect dose of a drug (knowledge error), or applying a rule incorrectly (rule-based error) Violations: deliberate deviation from rules or protocols; e.g., bypassing the drug check because of time pressure Contributory system factors: look-alike/sound-alike (LASA) drugs on the same shelf; similar ampoule appearance; illegible handwriting; unlabelled syringes; workload and fatigue; interruptions during drug preparation; inadequate monitoring B. Human Factors Framework in Anaesthesia 4 marks ⚙ Core Concept Human factors (also: ergonomics) is the scientific discipline that studies the interaction between humans and the systems they work within — with the goal of optimising human performance and reducing errors. In anaesthesia, human factors analysis recognises that the vast majority of ""human errors"" are precipitated or enabled by system failures, not personal failings. (Reason J — Human Error 1990; Helmreich RL — aviation safety to medicine; Flin R; RCOA human factors in anaesthesia) James Reason's Swiss Cheese Model Every defensive barrier in a system (training, protocols, checklists, monitoring, double-checks) has ""holes"" (weaknesses, failures); normally multiple barriers overlap and holes do not align; an adverse event occurs when all barriers fail simultaneously — holes align to create an uninterrupted pathway from hazard to harm; the key implication: errors are rarely the result of a single person failing — they result from system-wide weaknesses aligning; blame of the ""sharp-end"" individual is counterproductive — the ""blunt-end"" (organisational, management, design) failures must be addressed Human Factors Domain Application to Anaesthetic Drug Error Prevention Situational awareness (SA) The ability to perceive what is happening (Level 1), understand its meaning (Level 2), and project future states (Level 3); maintaining SA requires active scanning — checking monitors, reassessing drug labels, anticipating the next step; SA loss (""fixation error"") is a common precursor to drug errors in crisis situations (e.g., cardiac arrest → fixating on defibrillation → missing a drug dose error) Cognitive aids (checklists, protocols) Working memory is limited — under stress, normal cognitive capacity reduces dramatically; checklists offload memory to the system; WHO Surgical Safety Checklist; Stanford Emergency Manuals (Delphi-developed crisis checklists for MH, AFE, anaphylaxis, LAST); ISBAR handover structure; colour-coded syringe labels (AAGBI/ISO standard: opioids = blue, muscle relaxants = orange/red, hypnotics = yellow) Communication and teamwork Closed-loop communication — the receiver confirms receipt and reads back what was heard; avoids ""errors of commission"" where a drug is given because of a miscommunication; crew resource management (CRM) — aviation-derived: speak up culture, assertive follower (anyone in the team can challenge a decision), formal challenge-and-response for drug preparation; pre-operative briefing + debriefing (part of WHO checklist) Drug labelling and workspace design AAGBI recommendation: ALL syringes labelled before use with drug name, concentration, date/time, preparer; pre-filled labelled syringes reduce preparation errors; separate storage locations for LASA drugs (different shelf, staggered, coloured alerts); use of 10 mL syringes for IV and 20 mL syringes for epidural — prevents wrong-route errors (Luer-lock vs non-Luer connectors for epidural/enteral lines — NPSA guidance: use NRFit connector for neuraxial routes since 2020 — physically impossible to connect to an IV line) Fatigue and workload management Sleep deprivation → ↓ cognitive performance equivalent to alcohol intoxication at 24h awake; European Working Time Directive (max 48h/week) partially addresses this; handover standardisation (ISBAR) critical during fatigue-associated periods (night shifts, long cases) Simulation training Deliberate practice of rare, high-stakes events in a safe environment → builds pattern recognition and practised responses; simulation for malignant hyperthermia, anaphylaxis, LAST, laryngospasm, cannot intubate/cannot oxygenate — converts a novel scenario to a familiar one; reduces errors from ""first time in real life"" unpreparedness C. WHO Surgical Safety Checklist & Critical Incident Reporting 3 marks WHO Surgical Safety Checklist (2009) Background: developed by WHO as part of the Safe Surgery Saves Lives initiative (2008); Haynes et al. (NEJM 2009): implementation of the checklist in 8 hospitals globally → ↓ in-hospital mortality from 1.5% to 0.8% (47% reduction); ↓ complication rate from 11% to 7%; became mandatory in NHS England from February 2010 Three phases of the checklist: Sign In (before induction): patient confirmed identity, site, procedure, consent; site marked if applicable; anaesthesia machine and drugs checked; pulse oximeter applied and working; patient allergy check; difficult airway/aspiration risk assessment; blood loss >500 mL anticipated (≥7 mL/kg in children) — blood/fluids/warming equipment available? Time Out (before skin incision — ENTIRE TEAM pauses): confirmation of patient, procedure, site; surgeon, anaesthetist, nurse introduce themselves by name and role; surgeon states anticipated critical steps, blood loss, specific concerns; anaesthetist states specific patient concerns; nurse confirms sterility, equipment, other concerns; prophylactic antibiotic confirmation (given within last 60 minutes) Sign Out (before patient leaves operating room): nurse verbally confirms: procedure name recorded; instrument/swab/needle counts correct; specimen labelling; equipment problems to address; surgeon, anaesthetist, nurse review key recovery/post-op concerns Critical Incident Reporting Definition (Heinrich, aviation → medicine): a critical incident is any event or situation which did, or could have, led to unintended harm to a patient; includes ""near misses"" (prevented from causing harm by chance or intervention) — near misses are particularly valuable learning resources because they reveal system failures before harm occurs UK reporting systems: NRLS (National Reporting and Learning System) — national NHS incident reporting; AIMS (Anaesthesia Incident Monitoring Study — Australian/NZ; now global); SHOT (haemovigilance); NAP reports (National Audit Projects — RCOA/AAGBI — large-scale prospective audits: NAP3 [neuraxial complications], NAP4 [airway complications], NAP5 [awareness], NAP6 [anaphylaxis], NAP7 [perioperative cardiac arrest]) Principles of effective reporting systems: anonymous + non-punitive (Reason: ""blame-free culture"" — individuals report without fear of repercussion → ↑ reporting → more learning); standardised (structured report format); confidential; timely feedback to reporters (closes the learning loop); systemic analysis (root cause analysis — Ishikawa fishbone diagram identifies: people, methods, machines, materials, measurement, environment contributing to an error); shared learning nationally and internationally Morbidity and Mortality (M&M) meetings: departmental case review of adverse events; culture shift from ""name, blame, shame"" to systems analysis and learning; Safer Anaesthesia From Education (SAFE) — RCOA initiative promoting simulation and human factors training to reduce preventable harm Viva Corner Q. A colleague draws up what they believe is vecuronium but actually draws up suxamethonium — the patient receives it unexpectedly. Analyse this event using a human factors framework and outline what system changes could prevent recurrence. This is a classic wrong-drug (substitution) error — a slip-type error at the sharp end of care, but with multiple blunt-end system vulnerabilities. Analysis: (1) Immediate causation: the two ampoules are likely to be LASA (look-alike, sound-alike) — similar clear solutions, similar vial appearance, stored proximally; under the cognitive load of induction, pattern recognition shortcuts (""this ampoule is the right shape and is in the right location"") replaced careful label reading — a predictable consequence of human cognitive architecture, not personal incompetence. (2) Contributing system factors: ampoules stored together or in similar locations; no double-check protocol for neuromuscular blocking agents (high-alert drugs); no colour-coding or physical differentiation; time pressure at induction; no independent check by another team member. (3) Swiss Cheese analysis: multiple barriers (labelling system, storage separation, double-check, ampoule colour differentiation) all had holes that aligned — any one of these intact would have prevented the error. Recommended system changes: (a) Physical separation — suxamethonium stored in a locked refrigerator separately from other NMBDs; (b) Colour-coded labels — all NMBDs labelled with the AAGBI/ISO standard orange/red neuromuscular blocking agent sticker — applied during preparation; (c) ""Tall Man"" lettering — sUXAMethonium vs VECURONIUM — emphasises distinguishing letters; (d) Pre- drawn labelled syringes — using pharmacy-prepared standardised syringes where possible; (e) Double-check protocol for all high-alert drugs (NMBDs, high- concentration electrolytes, epidural drugs) — a second team member independently confirms drug and dose before administration; (f) Dedicated NMBD labelling — a bright orange warning sticker on all NMBD syringes reading ""NEUROMUSCULAR BLOCKING AGENT — CAUSES PARALYSIS""; (g) Simulation training for drug error recognition and management; (h) Incident report submitted to NRLS — data feeds into national learning and may trigger NPSA alert if a pattern is identified. ★ Examiner's Pearl Drug error incidence: 1 in 133 anaesthetics (Webster 2001); wrong drug = most common (40%). Reason's Swiss Cheese: errors occur when holes in multiple defensive barriers align; blame the system, not the individual. Human factors interventions: syringe labelling (ALL syringes labelled before use); NRFit connector for neuraxial (prevents wrong-route); LASA drug separation; closed-loop communication; CRM simulation training. WHO Checklist: Sign In + Time Out + Sign Out; Haynes NEJM 2009 — 47% ↓ mortality. Critical incident reporting: anonymous + non-punitive = ↑ reporting + learning. NAP reports: the gold standard of UK anaesthetic adverse event surveillance. References: Webster CS et al. The frequency and nature of drug administration error during anaesthesia (Anaesth Intensive Care 2001;29:494-500). Reason J. Human Error (Cambridge University Press 1990). Haynes AB et al. WHO Surgical Safety Checklist (NEJM 2009;360:491-499). Flin R et al. Anaesthesists' attitudes to teamwork and safety (Anaesthesia 2006;61:145- 151). NPSA. NRFit neuraxial connectors guidance 2020. RCOA NAP Reports series."